Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $59 | $82 | $133 | $137 |
| Short-Term Investments | $125 | $151 | $144 | $117 |
| Receivables | $48 | $36 | $30 | $28 |
| Inventory | $85 | $68 | $50 | $46 |
| Other Curr. Assets | $12 | $14 | $12 | $12 |
| Total Curr. Assets | $330 | $350 | $370 | $339 |
| Property Plant & Equip (Net) | $77 | $93 | $88 | $90 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $8 | $8 | $9 | $10 |
| Long-Term Investments | $0 | $6 | $6 | $7 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $47 | $38 | $36 | $33 |
| Total NC Assets | $132 | $145 | $138 | $140 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $462 | $495 | $508 | $478 |
| Liabilities | – | – | – | – |
| Payables | $12 | $5 | $5 | $14 |
| Short-Term Debt | $27 | $56 | $19 | $11 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $6 | $10 | $10 | $11 |
| Other Curr. Liab. | $34 | $23 | $35 | $54 |
| Total Curr. Liab. | $80 | $94 | $69 | $89 |
| LT Debt | $456 | $460 | $464 | $468 |
| Deferred Rev, NC | $0 | $68 | $71 | $70 |
| Deferred Tax Liab, NC | $0 | $37 | $39 | $0 |
| Other NC Liab. | $88 | $3 | $3 | $3 |
| Total NC Liab. | $545 | $531 | $538 | $541 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $52 | $61 | $46 | $49 |
| Total Liabilities | $625 | $625 | $607 | $630 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,207 | -$2,169 | -$2,132 | -$2,078 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $2,044 | $2,039 | $2,033 | $1,927 |
| Total Equity | -$163 | -$130 | -$99 | -$152 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $462 | $495 | $508 | $478 |
| Net Debt | $425 | $434 | $350 | $341 |